Transcatheter Aortic Valve Replacement innovative noninvasive treatment of aortic stenosis

Transcatheter Aortic Valve Replacement 

Introduction

• Newer innovative noninvasive treatment of Aortic Stenosis- Transcatheter Aortic Valve Replacement (TAVR)
• In August 2016, the Edwards Sapien XT and Sapien X3 were approved by the FDA for intermediate risk patients (STS score 4%- 8%). 
• In March 2017, Medtronic received FDA approval for the CoreValve Evolut Pro Valve for patients with severe aortic stenosis with intermediate risk, based on the SURTAVI Clinical Trial.

Focused Update of Valvular Heart Disease Guidelines from 2017 American Heart Association and American College of Cardiology

• TAVR is recommended for symptomatic patients with severe AS and a prohibitive risk for surgical aortic valve replacement (AVR) who have a predicted post-TAVR survival greater than 12 months. (Ia) 
• TAVR is recommended for symptomatic patients with severe AS and high risk for surgical AVR, depending on patient-specific procedural risks, values, and preferences. (Ia) 
• TAVR is a reasonable alternative to surgical AVR for symptomatic patients with severe AS and an intermediate surgical risk, depending on patient-specific procedural risks, values, and preferences. (IIa)